Analysts Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $370.86

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $370.86.

Several brokerages recently weighed in on UTHR. The Goldman Sachs Group increased their target price on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a report on Friday, November 1st. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. TD Cowen upped their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. Finally, HC Wainwright raised their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a report on Thursday, October 31st.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the transaction, the director now directly owns 5,655 shares of the company's stock, valued at approximately $2,332,574.40. This represents a 23.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 119,442 shares of company stock worth $44,577,770 in the last quarter. 11.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth $30,000. Innealta Capital LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth $33,000. USA Financial Formulas purchased a new position in shares of United Therapeutics in the third quarter worth $33,000. Finally, Brooklyn Investment Group bought a new position in shares of United Therapeutics during the third quarter valued at $33,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Trading Down 0.0 %

Shares of UTHR stock traded down $0.03 during trading hours on Thursday, hitting $374.37. 241,661 shares of the company's stock were exchanged, compared to its average volume of 452,964. United Therapeutics has a 12-month low of $208.62 and a 12-month high of $417.82. The company has a market capitalization of $16.72 billion, a PE ratio of 16.44, a PEG ratio of 1.07 and a beta of 0.54. The business's 50 day simple moving average is $368.58 and its 200-day simple moving average is $337.70.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. During the same quarter last year, the company earned $5.38 EPS. The firm's revenue was up 22.9% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics will post 25.22 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.